What Your PSA Actually Controls
Posted March 11, 2026 in Uncategorized
A commercial purchase and sale agreement is not a formality. It is the document that distributes financial risk, shapes closing obligations, and determines who bears the cost when something goes wrong before or after the deal closes. For developers, investors, and medical building owners, the PSA is where risk gets allocated first. It is also the last document most parties scrutinize carefully until a dispute is already underway.
What the Agreement Really Controls
Most parties focus on the purchase price and move on. What often goes unexamined are the provisions that determine strategic position when a problem surfaces:
- Due diligence termination rights. How broad are they, and what triggers a hard deadline?
- Environmental representations. What did the seller disclose, and what survives closing?
- Earnest money conditions. When is the deposit refundable, and when does it go hard?
- Title defect cure obligations. What must the seller fix, and by when?
- Indemnity caps and survival periods. How long after closing can a buyer bring a claim?
These provisions interact. A narrow due diligence window combined with a short survival period can leave a buyer with limited recourse if a material problem surfaces post-closing.
Due Diligence as a Negotiation Tool
Sophisticated buyers use the due diligence period as more than an inspection window. It is a renegotiation opportunity. If environmental testing reveals contamination, a phase I or phase II report becomes a basis for renegotiating terms, not just a reason to terminate.
The question is whether the PSA preserves that optionality. Some seller-drafted agreements limit termination rights to specific enumerated conditions. Others give buyers broad discretion. The difference matters when something surfaces mid-diligence that changes deal economics without being an outright dealbreaker.
Sellers in Colorado frequently try to limit environmental representations to “actual knowledge.” That language shifts a significant risk onto the buyer. If a seller misrepresents or fails to disclose a known condition, the fraud carveout in the indemnity provisions becomes the buyer’s primary avenue for recovery. Fraud carve-outs are not automatic. They have to be negotiated and clearly drafted. In disputes involving misrepresentation, how that provision reads determines whether litigation makes economic sense.
Failure to Close and Earnest Money Disputes
These are among the most litigated PSA issues. When a buyer fails to close, the seller’s typical remedy is to retain the earnest money as liquidated damages. When a seller fails to close, the buyer may seek specific performance, particularly when the property is unique or tied to a development timeline.
Earnest money disputes also arise when the parties disagree about whether a termination was proper. A buyer who terminates outside the due diligence window, or without a contractually permitted basis, may forfeit the deposit. The Colorado Real Estate Commission publishes contract form requirements for licensees, but commercial PSAs are heavily negotiated instruments that operate outside those standard forms.
Medical and Healthcare Real Estate Considerations
In transactions involving properties tied to licensed facilities, including medical office buildings, surgery centers, and specialty clinics, the PSA carries additional risk layers that general commercial deals do not.
Zoning and use restrictions have to be evaluated against the intended clinical use. A property zoned for general commercial occupancy may not permit certain healthcare operations without a conditional use permit or variance. If that issue surfaces post-closing and the seller made representations about permitted use, the buyer has a viable misrepresentation claim. If the seller was silent, the buyer’s recourse depends on how the “as-is” provisions were drafted.
In professional service environments where revenue depends on regulatory compliance and provider continuity, a delayed or failed closing is not just a financial event. It disrupts patient care timelines, equipment installation schedules, and staffing structures. The downstream operational cost of a failed deal can significantly exceed the earnest money at stake. A Denver business dispute lawyer who understands real estate transaction mechanics and regulated industry risk can assess these disputes early, before positions harden.
When to Litigate vs. When to Negotiate
Not every PSA dispute belongs in court. The analysis is economic. Litigation costs, time to resolution, and outcome uncertainty have to be weighed against what recovery is realistically available.
For earnest money disputes involving smaller deposits, negotiated resolution typically makes more financial sense. For disputes involving seller misrepresentation, fraud, or a failed closing on a high-value development site, the calculus shifts considerably. If the indemnity cap is too low relative to the actual loss, it affects both litigation strategy and settlement posture. That analysis should happen before a demand letter goes out, not after.
Working with a Denver business dispute lawyer early in a PSA dispute gives you a cleaner picture of your exposure, your realistic recovery range, and whether the economics of litigation actually support the fight.
Protecting Your Position Before Signing
The most effective PSA dispute prevention happens at the drafting stage. Positions worth negotiating include:
- Broad due diligence termination rights with clear refund mechanics
- Fraud carve-outs that survive the indemnity cap
- Survival periods long enough to uncover post-closing issues
- Specific performance as an available remedy for seller breach
- Clear title cure obligations with defined timelines and termination triggers
Volpe Law LLC works with developers, investors, and medical facility owners on commercial real estate contract disputes, from pre-closing negotiation through post-closing litigation. If a PSA issue is creating exposure you have not fully mapped, contact our team to discuss your matter.